Methods of molding intraocular lenses

Information

  • Patent Grant
  • 11690707
  • Patent Number
    11,690,707
  • Date Filed
    Wednesday, May 13, 2020
    4 years ago
  • Date Issued
    Tuesday, July 4, 2023
    a year ago
Abstract
Intraocular implants and methods of making intraocular implants are disclosed. The intraocular implant can include a mask adapted to increase depth of focus. The method of manufacturing the implant can include filling an annular mask-forming trough with an opaque mask material and adding an optically transmissive optic material over the opaque mask material.
Description
BACKGROUND

This application relates generally to the field of intraocular devices. More particularly, this application is directed to intraocular implants and lenses (IOLs) with an aperture to increase depth of focus (e.g., “masked” intraocular lenses), and methods of making the same.


DESCRIPTION OF THE RELATED ART

The human eye functions to provide vision by transmitting and focusing light through a clear outer portion called the cornea, and further refining the focus of the image onto a retina by way of a crystalline lens. The quality of the focused image depends on many factors including the size and shape of the eye, and the transparency of the cornea and the lens.


The optical power of the eye is determined by the optical power of the cornea and the crystalline lens. In a normal, healthy eye, sharp images of distant objects are formed on the retina (emmetropia). In many eyes, images of distant objects are either formed in front of the retina because the eye is abnormally long or the cornea is abnormally steep (myopia), or formed in back of the retina because the eye is abnormally short or the cornea is abnormally flat (hyperopia). The cornea also may be asymmetric or toric, resulting in an uncompensated cylindrical refractive error referred to as corneal astigmatism.


Some people suffer from cataracts in which the crystalline lens undergoes a loss of transparency. In such cases, the crystalline lens can be removed and replaced with an intraocular lens (IOL). However, some intraocular lenses may still leave defects in a patient's non-distance eyesight.


SUMMARY

Methods of manufacturing masked intraocular lenses can include a molding process. In general, the molding process can include pouring an uncured material into a mold and then curing the material with a combination of UV light and heat temperature cycles. However, when performing a molding process with both optically transmissive and opaque materials (e.g., an optically transmissive optic material and an opaque mask material), it can be difficult to produce precise border lines between the optic and the aperture, which can reduce the optical performance of the intraocular lens.


The present disclosure is generally related to methods of manufacturing a masked intraocular lens with an annular mask embedded within or positioned on an anterior or a posterior surface of the optic. The mask and the optic may comprise the same material, such as an acrylic copolymer or silicone. The methods disclosed herein produce a precise border line at the interface between inner and outer diameters of the mask and the optic.


The method of manufacturing the intraocular lens can include filling an annular mask-forming feature (e.g., a trough) with an opaque mask material, adding optically transmissive optic material over the opaque mask material; and fully curing the opaque mask material and the optically transmissive optic material to form a mask and an optic. The mask can be sufficiently thick to prevent transmission of at least 90% of incident visible light (or at least about 98% of incident visible light). The annular mask-forming feature can be provided in a lens mold or in a partially-formed optic.


Any feature, structure, or step disclosed herein can be replaced with or combined with any other feature, structure, or step disclosed herein, or omitted. Further, for purposes of summarizing the disclosure, certain aspects, advantages, and features of the inventions have been described herein. It is to be understood that not necessarily any or all such advantages are achieved in accordance with any particular embodiment of the inventions disclosed herein. No aspects of this disclosure are essential or indispensable.





BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments are depicted in the accompanying drawings for illustrative purposes, and should in no way be interpreted as limiting the scope of the embodiments. Furthermore, various features of different disclosed embodiments can be combined to form additional embodiments, which are part of this disclosure.



FIG. 1A illustrates an embodiment of a mask.



FIG. 1B illustrates another embodiment of the mask.



FIGS. 2A-2D illustrate an embodiment of an intraocular lens having a mask positioned on an anterior surface of the optic.



FIGS. 3A-3D illustrate another embodiment of an intraocular lens having a mask positioned on a posterior surface of the optic.



FIGS. 4A-4D illustrate yet another embodiment of an intraocular lens having a mask embedded in the optic.



FIG. 5 is a flow chart of a method of manufacturing an intraocular lens with a mask positioned on a surface of the optic.



FIG. 6 is a flow chart of a method of manufacturing an intraocular lens with a mask embedded in the optic.



FIG. 7 is a flow chart of another method of manufacturing an intraocular lens within a mask embedded in the optic.



FIGS. 8A-8E illustrate different embodiments of a mold delineator.



FIGS. 9A-9F illustrate a method of manufacturing an intraocular lens using the steps shown in FIG. 7.





DETAILED DESCRIPTION

Patients who undergo intraocular lens (IOL) implantation surgery may still suffer from defects in their non-distance eyesight (e.g., presbyopia). One technique for treating such defects is by including an annular mask within or on the optic that increases the patient's depth of focus. The light rays that pass through the aperture in the mask converge at a focal point on the retina, while the light rays that would not converge at the focal point on the retina are blocked by an opaque portion of the mask configured to prevent at least some or substantially all visible light from being transmitted through the mask.


Mask



FIG. 1A illustrates a mask 2034a having an annular region 2036a surrounding an aperture 2038a substantially centrally located on the mask 2034a. An anterior surface of the annular region 2036a can have a curvature from the outer periphery to the inner periphery of the annular region 2036a, and the posterior surface of the annular region 2036a can have a similar curvature. However, as shown in FIG. 1B, the mask 2034b can also be flat. The mask 2034b can include an annular region 2034b surrounding an aperture 2038b substantially centered on the optical axis 2039b of the mask 2034b. Although the features described below are described with respect to the mask 2034a, one or the more of the features may be applied to the mask 2034b.


In some embodiments, the outer periphery of the mask 2034a is generally circular with an outer diameter of at least about 3 mm and less than about 6 mm. In some embodiments, the diameter of the outer periphery of the mask 2034a is at least about 3 mm and less than or equal to about 4 mm.


A thickness of the mask 2034a can be constant or can vary between the inner periphery (near the aperture) and the outer periphery. For example, the thickness may increase from an outer periphery and/or inner periphery of the mask 2034a and toward a radial midline of the annular region 2036a. In general, the thickness at any location of the mask 2034a can be less than or equal to about 200 microns, or less than or equal to about 100 microns, but preferably between about 1 micron and about 20 microns. For example, the thickness of the mask 2034a can be within the range: from about 1 micron to about 40 microns, from about 5 microns to about 20 microns, from about 5 microns to about 15 microns. In some implementations, the thickness of the mask 2034a can be within about two microns of: about 15 microns, about 10 microns, about 8 microns, or about 5 microns.


The aperture 2038a can transmit substantially all incident visible light along the optical axis 2039a. For example, the aperture 2038a can be a through-hole in the annular region 2036a or a substantially light transmissive (e.g., transparent to visible light) portion thereof. The aperture 2038a can be substantially circular and/or substantially centered around the optical axis 2039a of the mask 2034a. The size of the aperture 2038a can be any size that is effective to increase the depth of focus of an eye of a patient with presbyopia. In particular, the size of the aperture 2038a can be dependent on the location of the mask within the eye (e.g., distance from the retina). In some implementations, the aperture 2038a can have a diameter of at least about 0.85 mm and less than or equal to about 2.2 mm, at least about 1.1 mm and less than or equal to about 1.6 mm, or at least about 1.3 mm and less than or equal to about 1.4 mm.


The annular region 2036a can prevent transmission of substantially all or at least a portion of the spectrum of the incident visible light (e.g., radiant energy in the electromagnetic spectrum that is visible to the human eye) and/or the spectrum of non-visible light (e.g., radiant energy outside the range visible to humans). Preventing transmission of visible light through the annular region 2036a can block light that would not converge at the retina and fovea to form a sharp image. In some implementations, the annular region 2036a can prevent transmission of at least about: 90 percent of incident visible light, 92 percent of incident visible light, 95 percent of incident visible light, 98 percent of all incident visible light, or 99 percent of all incident visible light. In other words, the annular region 2036a can transmit no more than about: 10 percent of incident visible light, 8 percent of incident visible light, 5 percent of incident visible light, 3 percent of incident visible light, 2 percent of incident visible light, or 1 percent of incident visible light.


In some embodiments, opacity of the annular region 2036a is achieved because the material used to make mask 2034a is naturally opaque. In other embodiments, the material used to make the mask 2034a may be naturally substantially clear but treated with a dye or other pigmentation agent (e.g., carbon black).


Further variations of masks can be found in U.S. Pat. No. 7,628,810, filed May 26, 2004, U.S. Publication No. 2012/0143325, filed Feb. 19, 2012, U.S. Publication No. 2011/0040376, filed Aug. 13, 2010; U.S. Publication No. 2013/0268071, filed Nov. 30, 2012; U.S. Publication No. 2014/0264981; U.S. Publication No. 2015/0073549, filed Aug. 7, 2014; U.S. Pat. No. 5,662,706, filed Jun. 14, 1996 U.S. Pat. No. 5,905,561, filed Jun. 14, 1996; and U.S. Pat. No. 5,965,330, filed Dec. 6, 1996, all of which are included in the Appendix.


Intraocular Lens


As shown in FIGS. 2A-2D, the intraocular lens 1000 includes an optic 1004 and a mask 1012. The optic 1004 can be formed from an optically transmissive material, while the mask can be formed from an opaque material.


The optic 1004 may be monofocal or multifocal and it can have positive or negative optical power. The optic 1004 may be aspheric or any other configuration as the context may dictate. In some implementations, the greatest thickness of the optic 1004 is at the center of the optic 1004. In other implementations, the optic 1004 may have a reduced thickness at its center, which is further described in U.S. Publication No. 2011/0040376, filed Aug. 13, 2010, and is included in the Appendix. The optic 1004 may be substantially circular with an outer diameter between about 5.0 mm and about 8.0 mm, such as about 6.0 mm. A central thickness of the optic 1004 can be less than or equal to about 1.0 mm, such as between about 0.75 mm and about 1.0 mm.


The intraocular lens 1000 may include one or more haptics 1008 (e.g., one, two, three, four, or more) to prevent the intraocular lens 1000 from moving or rotating within the eye. As used herein the term “haptic” is intended to be a broad term encompassing struts and other mechanical structures that can be opposed against an inner surface of an eye and mounted to an optic to securely position an intraocular lens in an optical path of an eye. The haptics 1008 can be a variety of shapes and sizes depending on the location the intraocular lens 1000 is implanted in the eye. The haptics 1008 may be C-shaped, J-shaped, plate design, or any other design. The haptics 1008 may be manufactured substantially flat or vaulted with respect to the optic. Variations on the shape of the optic and the haptics can be found in U.S. Publication No. 2011/0040376, filed Aug. 13, 2010, which is included in the Appendix.


The mask 1012 can be formed on an anterior surface 1016 of the optic 1004 (see FIGS. 2A-2D), on a posterior surface 1020 of the optic 1004 (see FIGS. 3A-3D), or embedded within the optic 1004 (see FIGS. 4A-4D). When the mask 1012 is embedded within the optic 1004, the mask 1012 can be formed substantially at the midway line between the posterior 1020 and anterior surfaces 1016 of the optic 1004. But the mask 1012 can also be formed at other locations within the optic 1004.


Methods of Manufacturing


In some embodiments, the optic 1004 can be formed by molding a liquid lens material, such as an acrylic or silicone material, and curing the material into a solid. A completed solid mask 1012 can be pre-manufactured (e.g., from a different material than the optic) and positioned on or in the optic as part of this molding process. However, in this type of process where the mask 1012 is pre-manufactured and then molded into the optic, there is a potential for an inadequate bond between the mask and the optic. In addition, if the mask and the optic are made of different materials, there is a potential that the optical performance of the intraocular lens can be compromised due to the mask and optic materials potentially having elasticities and/or thermal expansion properties, which are too dissimilar. For example, if the material properties of the optic 1004 and the mask 1012 are not adequately compatible, then deformations, such as those resulting from injection forces during surgical implantation or swelling that may occur during manufacture due to chemical extractions, may damage the intraocular lens. Similarly, temperature shifts that occur during manufacture and/or surgical implantation can also damage the intraocular lens.


It can therefore be advantageous to manufacture the intraocular lens using a process where the mask is molded from the same material as the optic (e.g., a liquid acrylic or silicone material) at the same general time and/or such that the mask and optic undergo similar curing sequences (e.g., the mask and optic can be at least partially cured together). For example, the mask can be formed from a liquid material that has been modified to be substantially opaque by mixing in a dark pigment dye or dark particles, whereas the optic can be formed from the unmodified transparent liquid material. In this type of manufacturing process, however, mixing, bleeding, and/or blending can occur between the opaque mask material and the transparent optic material. If this occurs, the outer and inner diameter borders of the mask can become blurred and/or diffuse. This can negatively impact the optical performance of the intraocular lens.


This mixing, bleeding, and/or blending of the opaque and transparent liquid materials can be reduced or prevented by providing a mask-forming feature in the lens mold which can help prevent the opaque material from spreading beyond the desired region where the mask is to be formed on the surface of the optic or within the optic. In some embodiments, the mask-forming feature can be an annular trough formed in the lens mold at the location where the mask is to be positioned. This mask-forming trough can have inner and outer diameters, which correspond to the desired size of the mask. The opaque material used to form the mask can be added to fill this trough. Transparent material used to form the optic can be added over or around the opaque material in the mask-forming trough. The trough can help to prevent the opaque material from mixing, bleeding, and/or blending with the transparent material in a way that would blur the outer or inner diameter of the mask. The trough can achieve this, for example, through surface tension, which helps to hold the opaque material in place. In this way, more precise mask borders can be achieved. For example, the inner border line of the mask (which defines the central circular aperture 2038) and the outer border line of the mask (which defines the outer circular perimeter of the mask 2034) can each be circular to within 100 microns (e.g., any location along the inner or outer border of the mask can be within 100 microns of a perfect circle [or within 75 microns, or within 50 microns, or within 25 microns]). In addition, the outer border and the inner border can be concentric to within ±200 microns (e.g., the outer border and the inner border at any given angular position can be within 200 microns of being perfectly concentric [or within 150 microns, or within 100 microns, or within 50 microns]).


When forming an intraocular lens with the mask positioned on an anterior or posterior surface of the optic, a lens forming surface of the lens mold can include a mask-forming feature located at a position where the mask is to be formed. The mask-forming feature can be generally annular and defined by an outer edge and an inner edge. These edges can be sharp knife edges in order to more effectively hold the opaque mask material in place via surface tension. The lens forming surface can also include an optic region positioned radially inward and/or outward of the mask-forming feature. As just mentioned, the mask-forming feature can be an annular trough. This trough can be etched, machined, or otherwise cut into the lens forming surface of the lens mold. The trough can have a minimum depth that creates a mask thickness which provides less than 5% light transmission (or less than 3% or less than 2%). In some embodiments, the depth of the trough can be at least about 4 microns, or between about 5 microns and about 10 microns. But the trough can be as deep as practically appropriate without causing dissimilar material property interactions between the mask material and the optic material, resulting in poor injection performance (e.g., a maximum trough depth of about 150 microns).


The optic region of the lens forming surface of the mold will generally be curved in order to provide the intraocular lens with refractive optical power. In such embodiments, the mask-forming feature can have a different radius of curvature than the optic region. This difference in radius of curvature can result in a trough in the lens forming surface to create the mask-forming feature and facilitate the creation of a precise border between the mask and the optic. The radius of curvature of the mask-forming feature can be between about 25% and about 50% of the radius of the optic region, such as between about 25% and 35%, between about 30% and about 40%, between about 35% and about 45%, between about 40% and about 50%, or otherwise. In some implementations, the radius of curvature of the mask-forming feature can be between about 30% and about 35% of the radius of the optic region, such as about 32%. In other embodiments, however, the mask-forming feature and the optic region can have the same radius of curvature, but can be separated by a stepped transition.



FIG. 5 is a flow chart illustrating a method of manufacturing an intraocular lens with a mask positioned on the anterior or posterior side of the optic. The method can include preparing a mixture of uncured mask material (e.g., an acrylic copolymer or silicone) mixed or impregnated with a high density of carbon black particles or other black dye or pigments as needed to provide opaque properties (e.g., to permit no more than about 2% light transmission). A specific and precise volume of uncured opaque mask material can be dispensed (e.g., with a cannula) to fill the mask-forming feature and define an outer diameter and an inner diameter of the mask (block 1050). By relying on surface tension and capillary action of the viscous mask material, the dispensed volume can be specifically controlled to conform to the outer and inner edges of the mask-forming feature of the mold. The exposed surface of the uncured mask material (i.e., opposite the lens forming surface) can exhibit a curvature. To achieve these results, the mask material can have a viscosity and/or surface tension that can range from approximately that of water to acetic acid per as specified below:















Absolute Viscosity
Surface Tension











Fluid
(N s/m2, Pa s)
(cp)
(104 lbm/ft sec)
mN/m





Acetic acid
0.0011550
1.155
7.760
27.60 @ 20 C


Water
0.0008900
0.890
6.000
71.95 @ 25 C









After filling the mask-forming feature, the mask can optionally be partially or fully cured using, for example, a combination of UV light and heat cycles (block 1052). Thereafter, the mold can be filled with an optically transmissive optic material, which may be the same as the mask material (e.g., acrylic or silicone), to over-mold the mask (block 1054). Finally, the mask material and the optic material can be fully cured-again, using a combination of UV light and heat cycles (block 1056).


In an alternative embodiment, the intraocular lens may be manufactured with the mask embedded within the optic. The method can include at least partially filling a first mold portion with an uncured optic material (block 1060). The first mold portion can be filled up to the depth where the mask is to be formed in the interior of the optic. In this way, the optic is initially only partially formed just to the thickness where the mask will be embedded in the completed optic. In this case, the first mold portion need not include a mask-forming feature. Instead, a second mold portion, which mates with the first mold portion, can include a structure that is the physical complement of the desired mask-forming feature. For example, the second mold portion can include an annular projection located where the mask is to be formed. The annular projection will form a trough in the partially-formed optic. As discussed further below, after at least partial curing of the optic material in the first mold portion, this trough in the partially-formed optic becomes the mask-forming feature and can be filled with opaque mask material.


After the first and second mold portions are mated together, the uncured transparent optic material can be partially or fully cured to form a trough in the interior surface of the partial optic (block 1062). The trough in the partial optic can be filled with an opaque mask material (block 1064). The opaque mask material can be prepared, for example, by mixing or impregnating an optically transmissive mask material (e.g., an acrylic copolymer or silicone) with a high density of carbon black particles or other black dye or pigments as needed to provide opaque properties (e.g., to permit no more than about 2% light transmission). A specific and precise volume of uncured opaque mask material can be dispensed (e.g., with a cannula) to exactly fill the trough in the partial optic and define an outer diameter and an inner diameter of the annular mask. By relying on surface tension and capillary action of the viscous mask material, the dispensed volume can be specifically controlled to conform to the outer and inner edges of the trough in the partial optic. The exposed surface of the uncured mask material (i.e., opposite interior surface of the optic) can exhibit a curvature. After filling the trough in the partial optic, the mask can optionally be partially or fully cured (block 1066). Thereafter, the mold can be filled with additional optic material to over-mold the mask (block 1068). A third mold portion can be used in place of the second mold portion to form an outer surface of the optic. Finally, the mask material and the optic material can be fully cured (block 1070). In some implementations, one of the mold portions may include a protruding pin that defines the inner diameter of the mask-forming feature and radially centers the mask in the optic.


An alternative method of manufacturing an intraocular lens with an embedded mask is illustrated in FIG. 7 and FIGS. 9A-9F. A measured partial volume of liquid type uncured optic material 2060 can be placed in a mold half 2062a (block 1080 and FIG. 9A). An edge border delineator 2050 can be placed on the center of the liquid optic material 2060 (block 1082 and FIG. 9B). A bead of opaque mask material 2064 can be dispensed within the lines of the edge border delineator 2050 (block 1084). The opaque mask material 2064 wicks to the confinements of the edge border delineator 2050 (FIG. 9C). Optionally, a bead of uncured optic material 2060 can be dispensed within the central aperture of the edge border delineator 2050 (FIG. 9D). The bead of optic material 2060 wicks to the inner periphery of the edge border delineator. At least the surface of the optic material 2060 can be partially cured at this time (block 1086). A measured partial volume of uncured optic material 2060 can be placed into the opposite mold half 2062b (block 1088). The two mold halves 2062a, 2062b can then be joined together and the intraocular lens can be put through the full curing process (block 1090 and FIG. 9E). Thereafter, the intraocular lens can be removed from the mold (FIG. 9F).



FIG. 8A illustrates an embodiment of the edge border delineator 2050. The edge border delineator 2050 can include an outer border 2052 spaced apart from an inner border 2054. As explained above, the opaque mask material can be dispensed between the outer border 2052 and the inner border 2054. The bead of optic material can be dispensed radially inward of the inner border 2054. The edge border delineator 2050 can be made from compatible polymer or elastic type polymer material (e.g., an acrylic copolymer or silicone). A width of the inner and/or outer border 2054, 2052 (e.g., in a radial direction) can be within a range of 100 microns to 500 microns. The thickness of the inner and/or outer border 2054, 2052 (e.g., in an anterior-posterior direction) can be between about 5 and 15 microns thick with a flat formed shape. Connecting spokes 2056 may or may not be used to maintain inner and outer border concentricity (see FIG. 8B). The cross-sectional profile of the inner and/or outer border 2054, 2052 can be vertical, stair stepped (see FIG. 8C), sloped (see FIG. 8D), fully contained (see FIG. 8E), or any other profile to facilitate the wicking/capillary action of the liquid acrylic as necessary. A plurality of mechanical locking holes can be provided in the edge border delineator to support capillary action and to minimize delamination of the intraocular during injection.


Terminology

Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.


The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.


The terms “approximately.” “about,” and “substantially” as used herein represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately,” “about,” and “substantially” may refer to an amount that is within less than 10% of the stated amount, as the context may dictate.


The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 3 mm” includes “3 mm.”


Although certain embodiments and examples have been described herein, it will be understood by those skilled in the art that many aspects of the methods and IOLs shown and described in the present disclosure may be differently combined and/or modified to form still further embodiments or acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. A wide variety of designs and approaches are possible. No feature, structure, or step disclosed herein is essential or indispensable.


For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. It is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.


Moreover, while illustrative embodiments have been described herein, the scope of any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations as would be appreciated by those in the art based on the present disclosure. The limitations in the claims are to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive. Further, the actions of the disclosed processes and methods may be modified in any manner, including by reordering actions and/or inserting additional actions and/or deleting actions. It is intended, therefore, that the specification and examples be considered as illustrative only, with a true scope and spirit being indicated by the claims and their full scope of equivalents.

Claims
  • 1. A method of manufacturing an intraocular lens, the method comprising: filling an annular mask-forming feature in a partially-formed optic with an opaque mask material;adding optically transmissive optic material over the opaque mask material; andfully curing the opaque mask material and the optically transmissive optic material to form a mask and an optic, the mask being sufficient to prevent transmission of at least 90% of incident visible light.
  • 2. The method of claim 1, further comprising, prior to filling the annular mask-forming feature with opaque mask material, forming the partially-formed optic by at least partially curing a dose of the optically transmissive optic material in a portion of a lens mold.
  • 3. The method of claim 1, further comprising preparing the opaque mask material by mixing an optically transmissive material with an opaque agent.
  • 4. The method of claim 3, wherein the optically transmissive material comprises acrylic.
  • 5. The method of claim 3, wherein the opaque agent comprises carbon black.
  • 6. The method of claim 1, further comprising at least partially curing the opaque mask material before adding the optically transmissive optic material over the opaque mask material.
  • 7. The method of claim 6, wherein at least partially curing the opaque mask material comprises fully curing the opaque mask material.
  • 8. The method of claim 1, wherein the mask is sufficient to prevent transmission of at least about 98% of incident visible light.
  • 9. The method of claim 1, wherein the opaque mask material and the optically transmissive optic material comprise the same material.
  • 10. The method of claim 9, wherein the same material comprises acrylic.
  • 11. The method of claim 1, wherein a surface of the annular mask-forming feature has a radius of curvature that is about 25% to about 50% of a radius of curvature of the optic.
  • 12. The method of claim 11, wherein the radius of curvature of the surface of the mask-forming feature is between about 30% and about 35% of the radius of curvature of the optic.
  • 13. The method of claim 1, wherein the optic is monofocal.
  • 14. The method of claim 1, wherein the annular mask-forming feature comprises a trough.
  • 15. The method of claim 1, wherein the annular mask-forming feature comprises a border delineator.
  • 16. An intraocular lens formed by the method of claim 1.
RELATED APPLICATIONS

This application is continuation of U.S. patent application Ser. No. 15/765,611, filed on Apr. 3, 2018 which is a national stage application based on International Application No. PCT/US2016/055207, filed Oct. 3, 2016, which claims priority benefit of U.S. Patent Application No. 62/237,429, filed Oct. 5, 2015, which is hereby incorporated by reference in its entirety herein.

US Referenced Citations (435)
Number Name Date Kind
2350421 Schoder et al. Jun 1944 A
2470927 Hale, Jr. May 1949 A
3034403 Neefe May 1962 A
3270099 Camp Aug 1966 A
3458870 Stone Aug 1969 A
3578850 Grant May 1971 A
3776230 Neefe Dec 1973 A
3794414 Wesley Feb 1974 A
3877502 Hunckler Apr 1975 A
3996627 Deeg et al. Dec 1976 A
4010496 Neefe Mar 1977 A
4104338 Guerrieri Aug 1978 A
4116439 Chavarria et al. Sep 1978 A
4210391 Cohen Jul 1980 A
4298996 Barnet Nov 1981 A
4340283 Cohen Jul 1982 A
4402579 Poler Sep 1983 A
4423728 Lieberman Jan 1984 A
4435050 Poler Mar 1984 A
4450593 Poler May 1984 A
4470159 Peyman Sep 1984 A
4505855 Bruns et al. Mar 1985 A
4512039 Lieberman Apr 1985 A
4563565 Kampfer et al. Jan 1986 A
4575373 Johnson Mar 1986 A
4596578 Kelman Jun 1986 A
4607617 Choyce Aug 1986 A
4624669 Grendahl Nov 1986 A
4639105 Neefe Jan 1987 A
4646720 Peyman et al. Mar 1987 A
4655774 Choyce Apr 1987 A
4665913 Esperance, Jr. May 1987 A
4669466 L'Esperance Jun 1987 A
4669834 Richter Jun 1987 A
4676790 Kern Jun 1987 A
4676791 LeMaster et al. Jun 1987 A
4678422 York Jul 1987 A
4701038 Neefe Oct 1987 A
4715858 Lindstrom Dec 1987 A
4767647 Bree Aug 1988 A
4795462 Grendahl Jan 1989 A
4798608 Grendahl Jan 1989 A
4799784 Safir Jan 1989 A
4799931 Lindstrom Jan 1989 A
4807623 Lieberman Feb 1989 A
4813955 Achatz et al. Mar 1989 A
4815690 Shepherd Mar 1989 A
4817789 Paul Apr 1989 A
4830855 Stewart May 1989 A
4842599 Bronstein Jun 1989 A
4842782 Portney Jun 1989 A
4851003 Lindstrom Jul 1989 A
4863466 Schlegel Sep 1989 A
4881860 Kanazawa Nov 1989 A
4903695 Warner et al. Feb 1990 A
4907586 Bille et al. Mar 1990 A
4928815 Paul May 1990 A
4955904 Atebara et al. Sep 1990 A
4976732 Vorosmarthy Dec 1990 A
4994080 Shepard Feb 1991 A
5013319 Davis May 1991 A
5030230 White Jul 1991 A
5034166 Rawlings et al. Jul 1991 A
5041133 Sayano et al. Aug 1991 A
5055602 Melpolder Oct 1991 A
5087015 Galley Feb 1992 A
5090955 Simon Feb 1992 A
5092880 Ohmi Mar 1992 A
5094521 Jolson et al. Mar 1992 A
5098443 Parel et al. Mar 1992 A
5108427 Majercik et al. Apr 1992 A
5112328 Taboada et al. May 1992 A
5120120 Cohen Jun 1992 A
5120121 Rawlings et al. Jun 1992 A
5137441 Fogarty Aug 1992 A
5147395 Willis Sep 1992 A
5171318 Gibson et al. Dec 1992 A
5185107 Blake Feb 1993 A
5188494 Hatin Feb 1993 A
5192316 Ting Mar 1993 A
5196026 Barrett et al. Mar 1993 A
5213749 Huss et al. May 1993 A
5260727 Oksman et al. Nov 1993 A
5266241 Parekh Nov 1993 A
5269795 Arnott Dec 1993 A
5269812 White Dec 1993 A
5274404 Michael Dec 1993 A
5288436 Liu et al. Feb 1994 A
5290892 Namdaran et al. Mar 1994 A
5292514 Capecchi et al. Mar 1994 A
5300116 Chirila et al. Apr 1994 A
5312330 Klopotek May 1994 A
5314439 Sugita May 1994 A
5314961 Anton et al. May 1994 A
5332802 Kelman et al. Jul 1994 A
5336261 Barrett et al. Aug 1994 A
5354331 Schachar et al. Oct 1994 A
5358520 Patel Oct 1994 A
5372580 Simon et al. Dec 1994 A
5391201 Barrett et al. Feb 1995 A
5441511 Hanna Aug 1995 A
5474548 Knopp et al. Dec 1995 A
5507740 O'Donnell, Jr. Apr 1996 A
5507806 Blake Apr 1996 A
5547468 Simon et al. Apr 1996 A
D375245 Irving Nov 1996 S
5578080 McDonald Nov 1996 A
5603774 LeBoeuf et al. Feb 1997 A
5607437 Simon et al. Mar 1997 A
5624456 Hellenkamp Apr 1997 A
5627613 Kaneko May 1997 A
5628794 Lindstrom May 1997 A
5628795 Langerman May 1997 A
5647865 Swinger Jul 1997 A
5652638 Roffman et al. Jul 1997 A
5653752 Silvestrini et al. Aug 1997 A
5662706 Legerton et al. Sep 1997 A
5674284 Chang et al. Oct 1997 A
5693268 Widman et al. Dec 1997 A
5697923 Poler Dec 1997 A
5702440 Portney Dec 1997 A
5708049 Katagiri et al. Jan 1998 A
5713957 Steele et al. Feb 1998 A
5722971 Peyman Mar 1998 A
5725575 O'Donnell, Jr. Mar 1998 A
5746558 Nygren et al. May 1998 A
5752967 Kritzinger et al. May 1998 A
5757458 Miller et al. May 1998 A
5769889 Kelman Jun 1998 A
5774202 Abraham et al. Jun 1998 A
5786883 Miller et al. Jul 1998 A
5824086 Silvestrini Oct 1998 A
5837156 Cumming Nov 1998 A
5843105 Mathis et al. Dec 1998 A
5864128 Plesko Jan 1999 A
5870167 Knopp et al. Feb 1999 A
5876442 Lipshitz et al. Mar 1999 A
5895610 Chang et al. Apr 1999 A
5905561 Lee et al. May 1999 A
5910537 Feingold et al. Jun 1999 A
5913898 Feingold et al. Jun 1999 A
5919185 Peyman Jul 1999 A
5925294 Shibuya Jul 1999 A
5964748 Peyman Oct 1999 A
5964776 Peyman Oct 1999 A
5965330 Evans et al. Oct 1999 A
5980040 Xu et al. Nov 1999 A
6017121 Chateau et al. Jan 2000 A
6063073 Peyman May 2000 A
6090141 Lindstrom Jul 2000 A
6102946 Nigam Aug 2000 A
6106553 Feingold et al. Aug 2000 A
6110166 Juhasz et al. Aug 2000 A
6138307 McDonald Oct 2000 A
6152959 Portney Nov 2000 A
6164777 Li et al. Dec 2000 A
6171336 Sawusch Jan 2001 B1
6178593 Carlson Jan 2001 B1
6197019 Peyman Mar 2001 B1
6201036 Fedorov et al. Mar 2001 B1
6203538 Peyman Mar 2001 B1
6210401 Lai Apr 2001 B1
6217571 Peyman Apr 2001 B1
6217596 Farah Apr 2001 B1
6221067 Peyman Apr 2001 B1
6228113 Kaufman May 2001 B1
6228114 Lee May 2001 B1
6228115 Hoffmann et al. May 2001 B1
6264648 Peyman Jul 2001 B1
6277146 Peyman et al. Aug 2001 B1
6280470 Peyman Aug 2001 B1
6280471 Peyman et al. Aug 2001 B1
6302877 Ruiz Oct 2001 B1
6304390 Takanashi Oct 2001 B1
6308590 Berto Oct 2001 B1
6335190 Zhou et al. Jan 2002 B1
6361560 Nigam Mar 2002 B1
6376153 Uchikawa et al. Apr 2002 B2
6387379 Goldberg et al. May 2002 B1
6391230 Sarbadhikari May 2002 B1
6416179 Lieberman et al. Jul 2002 B1
6423093 Hicks et al. Jul 2002 B1
6432246 Blake Aug 2002 B1
6436092 Peyman Aug 2002 B1
6458141 Peyman Oct 2002 B1
6461384 Hoffmann et al. Oct 2002 B1
6469844 Iwase et al. Oct 2002 B1
6480346 Funakoshi Nov 2002 B2
6491637 Foster et al. Dec 2002 B2
6497700 LaHaye Dec 2002 B1
6515006 Horn Feb 2003 B2
6533416 Fermigier et al. Mar 2003 B1
6551307 Peyman Apr 2003 B2
6554424 Miller et al. Apr 2003 B1
6554860 Hoffmann et al. Apr 2003 B2
6555103 Leukel et al. Apr 2003 B2
6575573 Lai et al. Jun 2003 B2
6581993 Nigam Jun 2003 B2
6588902 Isogai Jul 2003 B2
6589280 Koziol Jul 2003 B1
6607527 Ruiz et al. Aug 2003 B1
6613088 Babizhayev Sep 2003 B1
6638304 Azar Oct 2003 B2
6649722 Rosenzweig et al. Nov 2003 B2
6655804 Streibig Dec 2003 B2
6692126 Xie et al. Feb 2004 B1
6702807 Peyman Mar 2004 B2
6726322 Andino et al. Apr 2004 B2
6740116 Morcher May 2004 B2
6755858 White Jun 2004 B1
6786926 Peyman Sep 2004 B2
6811256 Becherer et al. Nov 2004 B1
6855163 Peyman Feb 2005 B2
6874886 Miller et al. Apr 2005 B2
6899424 Miller et al. May 2005 B2
6949093 Peyman Sep 2005 B1
6951556 Epstein Oct 2005 B2
6966648 Miller et al. Nov 2005 B2
6989008 Peyman Jan 2006 B2
6997428 Andino et al. Feb 2006 B1
7001374 Peyman Feb 2006 B2
7008447 Koziol Mar 2006 B2
7025455 Roffman Apr 2006 B2
7061693 Zalevsky Jun 2006 B2
7099057 Parker et al. Aug 2006 B2
7276080 Murakami et al. Oct 2007 B2
7287852 Fiala Oct 2007 B2
7364674 Hoover Apr 2008 B1
7399811 Mentak et al. Jul 2008 B2
7404637 Miller et al. Jul 2008 B2
7404638 Miller et al. Jul 2008 B2
7446157 Mentak et al. Nov 2008 B2
7455404 Bandhauer et al. Nov 2008 B2
7455691 Feingold et al. Nov 2008 B2
7462193 Nagamoto Dec 2008 B2
7477452 Tsuruma Jan 2009 B2
7491350 Silvestrini Jan 2009 B2
7497866 Perez Mar 2009 B2
7628810 Christie et al. Dec 2009 B2
7641337 Altmann Jan 2010 B2
7645299 Koziol Jan 2010 B2
7745555 Mentak et al. Jun 2010 B2
7780290 Zhao Aug 2010 B2
7842367 Mentak Nov 2010 B2
7976577 Silvestrini Jul 2011 B2
D645337 Hsu et al. Sep 2011 S
8043371 Paul et al. Oct 2011 B2
8048972 Mentak et al. Nov 2011 B2
8079706 Silvestrini et al. Dec 2011 B2
D656526 Christie et al. Mar 2012 S
8157374 Bandhauer et al. Apr 2012 B2
8241354 Hong et al. Aug 2012 B2
8287592 Silvestrini Oct 2012 B2
8343215 Miller et al. Jan 2013 B2
D681086 Christie et al. Apr 2013 S
8420753 Mentak et al. Apr 2013 B2
8439498 Zhao et al. May 2013 B2
8460374 Christie et al. Jun 2013 B2
8562131 Zhao Oct 2013 B2
8604098 Boydston et al. Dec 2013 B2
8740978 Weeber et al. Jun 2014 B2
8747466 Weeber et al. Jun 2014 B2
8752958 Miller et al. Jun 2014 B2
8633292 Hu et al. Jul 2014 B2
8858624 Christie et al. Oct 2014 B2
8864824 Silvestrini et al. Oct 2014 B2
8955968 Zalevsky et al. Feb 2015 B2
9005281 Christie et al. Apr 2015 B2
9138142 Christie et al. Sep 2015 B2
9204962 Silvestrini Dec 2015 B2
9427311 Christie et al. Aug 2016 B2
9427922 Reboul et al. Aug 2016 B2
9492272 Christie et al. Nov 2016 B2
9545303 Vilupuru et al. Jan 2017 B2
9573328 Reboul et al. Feb 2017 B2
9603704 Silvestrini Mar 2017 B2
9744077 Zicker et al. Aug 2017 B2
9757227 Kushlin et al. Sep 2017 B2
9844919 Reboul et al. Dec 2017 B2
9848979 Vilupuru et al. Dec 2017 B2
9943403 Webb et al. Apr 2018 B2
9987127 Bogaert et al. Jun 2018 B2
10183453 Reboul et al. Jan 2019 B2
10342656 Vilupuru et al. Jul 2019 B2
10350058 Silvestrini Jul 2019 B2
10426600 Coleman et al. Oct 2019 B2
10449036 Christie et al. Oct 2019 B2
10548717 Webb et al. Feb 2020 B2
10583619 Reboul et al. Mar 2020 B2
10687935 Webb et al. Jun 2020 B2
20010027314 Peyman Oct 2001 A1
20010034516 Peyman Oct 2001 A1
20010050750 Breger Dec 2001 A1
20020010510 Silverstrini Jan 2002 A1
20020082288 Horn Jun 2002 A1
20020120329 Lang et al. Aug 2002 A1
20020128710 Eggleston Sep 2002 A1
20020167640 Francis et al. Nov 2002 A1
20020196409 Jani Dec 2002 A1
20030014042 Juhasz et al. Jan 2003 A1
20030060880 Feingold Mar 2003 A1
20030105521 Perez Jun 2003 A1
20030135272 Brady et al. Jul 2003 A1
20030149480 Shadduck Aug 2003 A1
20030204258 Graham et al. Oct 2003 A1
20030216763 Patel Nov 2003 A1
20040019379 Glick et al. Jan 2004 A1
20040056371 Liao et al. Mar 2004 A1
20040068317 Knight Apr 2004 A1
20040106929 Masket Jun 2004 A1
20040140578 Kelly et al. Jul 2004 A1
20050027355 Murakami et al. Feb 2005 A1
20050046794 Silvestrini et al. Mar 2005 A1
20050056954 Devlin Mar 2005 A1
20050090895 Peyman Apr 2005 A1
20050124983 Frey et al. Jun 2005 A1
20050134793 Roffman Jun 2005 A1
20050137703 Chen Jun 2005 A1
20050143751 Makker et al. Jun 2005 A1
20050182488 Peyman Aug 2005 A1
20050187621 Brady Aug 2005 A1
20050288784 Peyman Dec 2005 A1
20060064077 Peyman Mar 2006 A1
20060079959 Christie et al. Apr 2006 A1
20060113054 Silvestrini Jun 2006 A1
20060135477 Haitjema et al. Jun 2006 A1
20060184243 Yilmaz Aug 2006 A1
20060232665 Schowengerdt et al. Oct 2006 A1
20060235428 Silvestrini Oct 2006 A1
20060235514 Silvestrini Oct 2006 A1
20060241751 Marmo et al. Oct 2006 A1
20060247659 Moeller et al. Nov 2006 A1
20060265058 Silvestrini Nov 2006 A1
20060268226 Christie et al. Nov 2006 A1
20060268227 Christie et al. Nov 2006 A1
20060268228 Christie et al. Nov 2006 A1
20060268229 Silvestrini et al. Nov 2006 A1
20060270946 Silvestrini et al. Nov 2006 A1
20060271026 Silvestrini et al. Nov 2006 A1
20060271178 Christie et al. Nov 2006 A1
20060271179 Christie et al. Nov 2006 A1
20060271180 Christie et al. Nov 2006 A1
20060271181 Christie et al. Nov 2006 A1
20060271182 Christie et al. Nov 2006 A1
20060271183 Christie et al. Nov 2006 A1
20060271184 Silvestrini Nov 2006 A1
20060271185 Silvestrini Nov 2006 A1
20060274264 Christie et al. Dec 2006 A1
20060274265 Christie et al. Dec 2006 A1
20070032866 Portney Feb 2007 A1
20070091472 Alkemper et al. Apr 2007 A1
20070092592 Chiang Apr 2007 A1
20070129797 Lang et al. Jun 2007 A1
20070225691 Silvestrini et al. Sep 2007 A1
20080033546 Liang Feb 2008 A1
20080077238 Deacon et al. Mar 2008 A1
20080100921 Nishikawa May 2008 A1
20080151183 Altmann Jun 2008 A1
20080208335 Blum et al. Aug 2008 A1
20080212030 Bentley et al. Sep 2008 A1
20080220214 Uozu et al. Sep 2008 A1
20080221674 Blum et al. Sep 2008 A1
20080255663 Akpek et al. Oct 2008 A1
20080269884 Vannoy Oct 2008 A1
20080306587 Your Dec 2008 A1
20090012505 Chernyak Jan 2009 A1
20090021692 Miller et al. Jan 2009 A1
20090287306 Smith et al. Jan 2009 A1
20090036880 Bischoff et al. Feb 2009 A1
20090048608 Boukhny et al. Feb 2009 A1
20090059168 Miller et al. Mar 2009 A1
20090069817 Peyman Mar 2009 A1
20090164008 Hong et al. Jun 2009 A1
20090171458 Kellan et al. Jul 2009 A1
20090187242 Weeber et al. Jul 2009 A1
20090204207 Blum et al. Aug 2009 A1
20090213326 Zhao Aug 2009 A1
20090222086 Lui et al. Sep 2009 A1
20090234448 Weeber et al. Sep 2009 A1
20090279048 Hong et al. Nov 2009 A1
20090306773 Silvestrini et al. Dec 2009 A1
20090323020 Zhao et al. Dec 2009 A1
20100016961 Hong et al. Jan 2010 A1
20100016965 Hong et al. Jan 2010 A1
20100082100 Mikawa Apr 2010 A1
20100127412 Lake May 2010 A1
20100149618 Sprague Jun 2010 A1
20100208199 Levis et al. Aug 2010 A1
20100225014 Bille Sep 2010 A1
20100312336 Hong et al. Dec 2010 A1
20110037184 Shoji et al. Feb 2011 A1
20110040376 Christie et al. Feb 2011 A1
20110051080 Bandhauer et al. Mar 2011 A1
20110125261 Portney May 2011 A1
20110166652 Bogaert et al. Jul 2011 A1
20110172675 Danta et al. Jul 2011 A1
20110245919 Pettit Oct 2011 A1
20110251685 Chu Oct 2011 A1
20110292340 Shimizu et al. Dec 2011 A1
20120203239 Vukich et al. Aug 2012 A1
20120245683 Christie et al. Sep 2012 A1
20120309761 Chow et al. Dec 2012 A1
20120310338 Christie et al. Dec 2012 A1
20130053953 Silvestrini Feb 2013 A1
20130131795 Miller et al. May 2013 A1
20130147072 Bothe et al. Jun 2013 A1
20130238091 Danta et al. Sep 2013 A1
20130289543 Mordaunt Oct 2013 A1
20140121767 Simpson May 2014 A1
20140131905 Webb May 2014 A1
20140200666 Phillips Jul 2014 A1
20140336625 Fernandez Nov 2014 A1
20140343541 Scott et al. Nov 2014 A1
20140379078 Trindade Dec 2014 A1
20150025627 Christie et al. Jan 2015 A1
20150046094 Chaudhary et al. Feb 2015 A1
20150073549 Webb et al. Mar 2015 A1
20150177422 Liu et al. Jun 2015 A1
20150183173 Linhardt et al. Jul 2015 A1
20150250583 Rosen et al. Sep 2015 A1
20150366658 Christie et al. Dec 2015 A1
20160100938 Bogaert et al. Apr 2016 A1
20160135947 Webb et al. May 2016 A1
20160297107 Shim et al. Oct 2016 A1
20170049560 Cherne Feb 2017 A1
20170143477 Christie et al. May 2017 A1
20180125639 Vilupuru et al. May 2018 A1
20180133990 Reboul et al. May 2018 A1
20180296322 Webb et al. Oct 2018 A1
20180338826 Link et al. Nov 2018 A1
20190076241 Alarcon Heredia et al. Mar 2019 A1
20190193350 Gu et al. Jun 2019 A1
20190269499 Ellis Sep 2019 A1
20200000576 Christie et al. Jan 2020 A1
20200179105 Waterhouse et al. Jun 2020 A1
Foreign Referenced Citations (137)
Number Date Country
2004201751 May 2004 AU
1734305 Feb 2006 CN
1875895 Dec 2006 CN
100368846 Feb 2008 CN
101322663 Dec 2008 CN
101341426 Jul 2012 CN
203647535 Jun 2014 CN
2727410 Dec 1978 DE
4134320 Apr 1992 DE
0165652 Dec 1985 EP
0443094 Aug 1991 EP
1173790 Jan 2002 EP
1674049 Jun 2006 EP
1548489 Aug 2006 EP
2111822 Oct 2009 EP
2319457 May 2011 EP
2243052 Sep 2011 EP
2365379 Sep 2011 EP
2455799 May 2012 EP
2823789 Jan 2015 EP
2364457 Aug 2015 EP
2993514 Mar 2016 EP
2349150 Jul 2016 EP
2620687 Mar 1989 FR
2649605 Jan 1991 FR
1276003 Jun 1972 GB
2507465 May 2014 GB
62-167343 Jul 1987 JP
64-002644 Jan 1989 JP
H01-195852 Aug 1989 JP
H02-7954 Jan 1990 JP
04-158859 Jun 1992 JP
06-509731 Mar 1993 JP
H05-65340 Sep 1993 JP
06-502782 Mar 1994 JP
H07-067896 Mar 1995 JP
07-265340 Oct 1995 JP
08-103457 Apr 1996 JP
H09-502542 Mar 1997 JP
11-503657 Aug 1997 JP
07-178125 Jul 1998 JP
2000-047145 Feb 2000 JP
2002-537895 Nov 2002 JP
2003-502109 Jan 2003 JP
2004-510199 Apr 2004 JP
2004-538034 Dec 2004 JP
2005-533576 Nov 2005 JP
2007-516794 Jun 2007 JP
2007-523720 Aug 2007 JP
2008-506710 Mar 2008 JP
S59-54527 May 2008 JP
10-0335722 May 2002 KR
2138837 Sep 1999 RU
110978 Mar 2011 RU
2456968 Jul 2012 RU
2457812 Aug 2012 RU
2459598 Aug 2012 RU
2493801 Sep 2013 RU
134049 Nov 2013 RU
134784 Nov 2013 RU
2500368 Dec 2013 RU
2511081 Apr 2014 RU
2517488 May 2014 RU
1380743 Mar 1988 SU
201103518 Feb 2011 TW
WO 8705797 Oct 1987 WO
WO 9503747 Feb 1995 WO
WO 9508135 Mar 1995 WO
WO 9635397 Nov 1996 WO
WO 9848715 Nov 1998 WO
WO 00025704 May 2000 WO
WO 00038594 Jul 2000 WO
WO 0051682 Sep 2000 WO
WO 0052516 Sep 2000 WO
WO 0070388 Nov 2000 WO
WO 2001010641 Feb 2001 WO
WO 0115779 Mar 2001 WO
WO 0117460 Mar 2001 WO
WO 0119364 Mar 2001 WO
WO 01082815 Nov 2001 WO
WO 02076320 Oct 2002 WO
WO 02102241 Dec 2002 WO
WO 03020177 Mar 2003 WO
WO 03022168 Mar 2003 WO
WO 03061518 Jul 2003 WO
WO 2004014969 Feb 2004 WO
WO 2004034917 Apr 2004 WO
WO 2004105588 Dec 2004 WO
WO 2004113959 Dec 2004 WO
WO 2005082265 Sep 2005 WO
WO 2006020638 Feb 2006 WO
WO 2006047534 May 2006 WO
WO 2006060380 Jun 2006 WO
WO 2006069012 Jun 2006 WO
WO 2006113377 Oct 2006 WO
WO 2006113411 Oct 2006 WO
WO 2006113563 Oct 2006 WO
WO 2006113564 Oct 2006 WO
WO 2007057734 Oct 2007 WO
WO 2007133384 Nov 2007 WO
WO 2007142981 Dec 2007 WO
WO 2008036671 Mar 2008 WO
WO 2008102096 Aug 2008 WO
WO 2009050511 Apr 2009 WO
WO 2009122409 Oct 2009 WO
WO 2009140080 Nov 2009 WO
WO 2009149060 Dec 2009 WO
WO 2010002215 Jan 2010 WO
WO 2010059214 May 2010 WO
WO 2010118469 Oct 2010 WO
WO 2011020074 Feb 2011 WO
WO 2011020078 Feb 2011 WO
WO 2011047076 Apr 2011 WO
WO 2011069059 Jun 2011 WO
WO 2011088107 Jul 2011 WO
WO 2012170066 Dec 2012 WO
WO 2011030509 Feb 2013 WO
WO 2013019871 Feb 2013 WO
WO 2013082545 Jun 2013 WO
WO 2013101793 Jul 2013 WO
WO 2013112589 Aug 2013 WO
WO 2013123265 Aug 2013 WO
WO 2014054946 Apr 2014 WO
WO 2014074610 May 2014 WO
WO 2014158653 Oct 2014 WO
WO 2014164056 Oct 2014 WO
WO 2014195059 Dec 2014 WO
WO 2015021323 Feb 2015 WO
WO 2015069927 May 2015 WO
WO 2015073718 May 2015 WO
WO 2015078271 Jun 2015 WO
WO 2015086611 Jun 2015 WO
WO 2016081493 May 2016 WO
WO 2015108156 Mar 2017 WO
WO 2017062316 Apr 2017 WO
WO 2017091520 Jun 2017 WO
WO 2019010178 Jan 2019 WO
Non-Patent Literature Citations (7)
Entry
Internet Archive Wayback Machine; Aniridia Implants; downloaded from https://web.archive.org/web/20110824062840/http://www.morcher.com/nc/produkte/aniridiaimplants.html (Archived Aug. 24, 2011; printed on Feb. 5, 2015).
Guyton A.C., Textbook of Medical Physiology, 7th Edition, W.B. Saunders Company, Jan. 1986: Chapter 58, in 13 pages.
International Search Report and Written Opinion for PCT/US2016/055207 dated Jan. 18, 2017 in 15 pages.
Lu Xuequan, et al. “Radiation preparation and thermo-response swelling of interpenetrating polymer network hydrogel composed of PNIPAAm and PMMA”, Radiation Physics and Chemistry, vol. 57, Mar. 2000, pp. 477-480, XP002473596.
Patel, C.K., et al. “Imaging the macula through a black occlusive intraocular lens”. Arch. Ophthalmol. Oct. 2010; 128(10):1374-1376.
Yusuf, et al., “Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use”, J. Cataract Refract. Surg., Mar. 2012, 38: 513-518.
Yusuf, et al., “Occlusive IOLs for Intractable Diplopia Demonstrate a Novel Near-Infrared Window of Transmission for SLO/OCT Imaging and Clinical Assessment”. Investigative Ophthalmology & Visual Science, May 2011, 52(6): 3737-3743.
Related Publications (1)
Number Date Country
20200337831 A1 Oct 2020 US
Provisional Applications (1)
Number Date Country
62237429 Oct 2015 US
Continuations (1)
Number Date Country
Parent 15765611 US
Child 15931289 US